Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trialResearch in context

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trialResearch in context

Summary: Background: Daily methadone maintenance or buprenorphine treatment is the standard-of-care (SoC) medication for opioid use disorder (OUD). Subcutaneously injected, extended-release buprenorphine (BUP-XR) may be more effective—but there has been no superiority evaluation. Methods: This prag...

Full description

Bibliographic Details
Main Authors: John Marsden, Mike Kelleher, Eilish Gilvarry, Luke Mitcheson, Jatinder Bisla, Angela Cape, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Will Hardy, Andrea Hearn, Joanna Kelly, Natalie Lowry, Martin McCusker, Caroline Murphy, Robert Murray, Tracey Myton, Sophie Quarshie, Rob Vanderwaal, April Wareham, Dyfrig Hughes, Zoë Hoare
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:EClinicalMedicine
Subjects:
Opioid use disorder
Standard of care
Extended-release buprenorphine
Effectiveness
Cost-effectiveness
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023004881

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023004881

Similar Items